All In Biotech

Drug Trial Radar · NCT00287183

6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria

Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multicenter Study In Patients With Type 2 Diabetes And Persistent Albuminuria To Evaluate The Safety And Efficacy Of A Six Month Regimen Of Orally-Administered TTP488

Last checked: Nov 19, 2026Latest source record: Oct 1, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

Feb 2006

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Feb 6, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 31 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Current research indicates that TTP488 may be a viable agent for the treatment of diabetic nephropathy. The purpose of this study is to determine the safety and efficacy of a six-month regimen of daily orally-administered TTP488 to patients with diabetic nephropathy.

Conditions

  • Diabetic Nephropathy

Interventions

  • PF-04494700 (TTP488)Drug

    60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary endpoint of efficacy will be assessed by comparing the treatment groups based on the change in urinary albumin-creatinine ratio (UACR)Time frame: from baseline to end of treatment (Month 6).

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Red Deer, Alberta, Canada

  • Pfizer Investigational Site

    Penticton, British Columbia, Canada

  • Pfizer Investigational Site

    Vancouver, British Columbia, Canada

  • Pfizer Investigational Site

    Burlington, Ontario, Canada

  • Pfizer Investigational Site

    Courtice, Ontario, Canada

  • Pfizer Investigational Site

    Fort Erie, Ontario, Canada

  • Pfizer Investigational Site

    Hamilton, Ontario, Canada

  • Pfizer Investigational Site

    Kitchener, Ontario, Canada

  • Pfizer Investigational Site

    Kitchener, Ontario, Canada

  • Pfizer Investigational Site

    Millon, Ontario, Canada

  • Pfizer Investigational Site

    North Bay, Ontario, Canada

  • Pfizer Investigational Site

    Oakville, Ontario, Canada

  • Pfizer Investigational Site

    Saint Catherines, Ontario, Canada

  • Pfizer Investigational Site

    Scarborough Village, Ontario, Canada

  • Pfizer Investigational Site

    Smith Falls, Ontario, Canada

  • Pfizer Investigational Site

    Thornhill, Ontario, Canada

  • Pfizer Investigational Site

    Toronto, Ontario, Canada

  • Pfizer Investigational Site

    Toronto, Ontario, Canada

  • Pfizer Investigational Site

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.